Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
7(50%)
Results Posted
100%(5 trials)
Terminated
1(7%)

Phase Distribution

Ph phase_1
2
14%
Ph phase_4
1
7%
Ph phase_3
2
14%
Ph phase_2
4
29%

Phase Distribution

2

Early Stage

4

Mid Stage

3

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
2(22.2%)
Phase 2Efficacy & side effects
4(44.4%)
Phase 3Large-scale testing
2(22.2%)
Phase 4Post-market surveillance
1(11.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

7

trials recruiting

Total Trials

14

all time

Status Distribution
Active(8)
Completed(5)
Terminated(1)

Detailed Status

Completed5
Recruiting5
Active, not recruiting2
Not yet recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
14
Active
7
Success Rate
83.3%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (22.2%)
Phase 24 (44.4%)
Phase 32 (22.2%)
Phase 41 (11.1%)

Trials by Status

completed536%
active_not_recruiting214%
not_yet_recruiting17%
terminated17%
recruiting536%

Recent Activity

Clinical Trials (14)

Showing 14 of 14 trials
NCT07088068Phase 3

A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes

Recruiting
NCT07457580

Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs)

Recruiting
NCT07360080

Long-Term Outcomes of Teplizumab in Routine Clinical Care

Recruiting
NCT06791291Phase 2

Efficacy and Safety of Teplizumab in Japanese Participants With Stage 2 Type 1 Diabetes

Recruiting
NCT07216391Phase 2

Platform Trial to Delay Stage 3 Diabetes: Comparing Teplizumab With ATG

Not Yet Recruiting
NCT05757713Phase 4

Teplizumab in Pediatric Stage 2 Type 1 Diabetes

Active Not Recruiting
NCT04598893

Recent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of Teplizumab (PROTECT Extension)

Active Not Recruiting
NCT07260110

A Longitudinal, Observational Study Comparing Real-World Experiences of Teplizumab-Treated and Untreated Participants With Stage 2 Type 1 Diabetes in the United States

Recruiting
NCT06892002

Description of Patients With Type 1 Diabetes Treated With Teplizumab

Completed
NCT03875729Phase 3

Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab

Completed
NCT00385697Phase 2

The Protégé Study - Clinical Trial of MGA031 in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus

Completed
NCT03751007Phase 1

A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recent-onset Diagnosed Type 1 Diabetes (T1D)

Completed
NCT00954915Phase 1

Safety Study of the Monoclonal Antibody Teplizumab (MGA031) in Subjects With Moderate or More Severe Psoriasis

Terminated
NCT01030861Phase 2

Teplizumab for Prevention of Type 1 Diabetes In Relatives "At-Risk"

Completed

All 14 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
14